-
Je něco špatně v tomto záznamu ?
Clinicopathological features, MCPyV status and outcomes of Merkel cell carcinoma in solid-organ transplant recipients: a retrospective, multicentre cohort study
C. Ferrándiz-Pulido, A. Gómez-Tomás, B. Llombart, D. Mendoza, J. Marcoval, S. Piaserico, C. Baykal, JN. Bouwes-Bavinck, E. Rácz, J. Kanitakis, CA. Harwood, P. Cetkovská, A. Geusau, V. Del Marmol, E. Masferrer, C. Orte Cano, J. Ricar, WR. de...
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, multicentrická studie
PubMed
35607918
DOI
10.1111/jdv.18256
Knihovny.cz E-zdroje
- MeSH
- infekce onkogenními viry * komplikace MeSH
- lidé MeSH
- Merkelův nádor * patologie MeSH
- Merkelův polyomavirus * MeSH
- nádory kůže * patologie MeSH
- polyomavirové infekce * MeSH
- retrospektivní studie MeSH
- TOR serin-threoninkinasy MeSH
- transplantace orgánů * škodlivé účinky MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
BACKGROUND: The proportion of Merkel cell carcinomas (MCCs) in solid-organ transplant recipients (SOTR) harbouring Merkel cell polyomavirus (MCPyV) is unknown, as are factors affecting their outcomes. OBJECTIVE: To describe clinicopathological features of MCC in SOTR, investigate the tumoral MCPyV-status and identify factors associated with tumour outcomes. METHODS: Retrospective, international, cohort-study. MCPyV-status was investigated by immunohistochemistry and polymerase chain reaction. RESULTS: A total of 30 SOTR and 44 consecutive immunocompetent patients with MCC were enrolled. SOTR were younger at diagnosis (69 vs. 78 years, P < 0.001). Thirty-three percent of SOTR MCCs were MCPyV-positive vs. 91% of immunocompetent MCCs (P = 0.001). Solid-organ transplantation was associated with an increased cumulative incidence of progression (SHR: 3.35 [1.57-7.14], P = 0.002), MCC-specific mortality (SHR: 2.55 [1.07-6.06], P = 0.034) and overall mortality (HR: 3.26 [1.54-6.9], P = 0.002). MCPyV-positivity and switching to an mTOR inhibitor (mTORi) after MCC diagnosis were associated with an increased incidence of progression (SHR: 4.3 [1.5-13], P = 0.008 and SHR: 3.6 [1.1-12], P = 0.032 respectively) in SOTR. LIMITATIONS: Retrospective design and heterogeneity of SOTR cohort. CONCLUSIONS: MCPyV appears to play a less prominent role in the aetiopathogenesis of MCC in SOTR. SOTR have a worse prognosis than their immunocompetent counterparts and switching to an mTORi after the diagnosis of MCC does not improve progression.
Department of Dermatology Başkent University Faculty of Medicine Ankara Turkey
Department of Dermatology Edouard Herriot Hospital Group Hospices Civils de Lyon Lyon France
Department of Dermatology Fundación Jiménez Díaz Madrid Spain
Department of Dermatology Hospital de Bellvitge IDIBELL University of Barcelona Barcelona Spain
Department of Dermatology Hospital Universitari Mútua de Terrassa Barcelona Spain
Department of Dermatology Istanbul University Istanbul Medical Faculty Istanbul Turkey
Department of Dermatology Leiden University Medical Center Leiden The Netherlands
Department of Dermatology Medical University of Vienna Vienna Austria
Department of Dermatology University of São Paulo São Paul Brazil
Department of Dermatovenereology Faculty of Medicine Charles University Pilsen The Czech Republic
Dermatology Unit Department of Medicine Università di Padova Padova Italy
Dermatopathologie Friedrichshafen Germany
IVO CIPF Joint Research Unit of Cancer Príncipe Felipe Research Center Valencia Spain
Laboratory of Molecular Biology Fundación Instituto Valenciano de Oncología Valencia Spain
Service de Dermatologie Hôpital Erasme Université Libre de Bruxelles Brussels Belgium
Servicio de Dermatología Instituto Valenciano de Oncología Valencia Spain
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22032924
- 003
- CZ-PrNML
- 005
- 20230131150918.0
- 007
- ta
- 008
- 230120s2022 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1111/jdv.18256 $2 doi
- 035 __
- $a (PubMed)35607918
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Ferrándiz-Pulido, C $u Department of Dermatology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain $1 https://orcid.org/0000000336889596
- 245 10
- $a Clinicopathological features, MCPyV status and outcomes of Merkel cell carcinoma in solid-organ transplant recipients: a retrospective, multicentre cohort study / $c C. Ferrándiz-Pulido, A. Gómez-Tomás, B. Llombart, D. Mendoza, J. Marcoval, S. Piaserico, C. Baykal, JN. Bouwes-Bavinck, E. Rácz, J. Kanitakis, CA. Harwood, P. Cetkovská, A. Geusau, V. Del Marmol, E. Masferrer, C. Orte Cano, J. Ricar, WR. de Oliveira, R. Salido-Vallejo, E. Ducroux, MA. Gkini, JA. López-Guerrero, H. Kutzner, W. Kempf, D. Seçkin
- 520 9_
- $a BACKGROUND: The proportion of Merkel cell carcinomas (MCCs) in solid-organ transplant recipients (SOTR) harbouring Merkel cell polyomavirus (MCPyV) is unknown, as are factors affecting their outcomes. OBJECTIVE: To describe clinicopathological features of MCC in SOTR, investigate the tumoral MCPyV-status and identify factors associated with tumour outcomes. METHODS: Retrospective, international, cohort-study. MCPyV-status was investigated by immunohistochemistry and polymerase chain reaction. RESULTS: A total of 30 SOTR and 44 consecutive immunocompetent patients with MCC were enrolled. SOTR were younger at diagnosis (69 vs. 78 years, P < 0.001). Thirty-three percent of SOTR MCCs were MCPyV-positive vs. 91% of immunocompetent MCCs (P = 0.001). Solid-organ transplantation was associated with an increased cumulative incidence of progression (SHR: 3.35 [1.57-7.14], P = 0.002), MCC-specific mortality (SHR: 2.55 [1.07-6.06], P = 0.034) and overall mortality (HR: 3.26 [1.54-6.9], P = 0.002). MCPyV-positivity and switching to an mTOR inhibitor (mTORi) after MCC diagnosis were associated with an increased incidence of progression (SHR: 4.3 [1.5-13], P = 0.008 and SHR: 3.6 [1.1-12], P = 0.032 respectively) in SOTR. LIMITATIONS: Retrospective design and heterogeneity of SOTR cohort. CONCLUSIONS: MCPyV appears to play a less prominent role in the aetiopathogenesis of MCC in SOTR. SOTR have a worse prognosis than their immunocompetent counterparts and switching to an mTORi after the diagnosis of MCC does not improve progression.
- 650 12
- $a Merkelův nádor $x patologie $7 D015266
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a Merkelův polyomavirus $7 D059965
- 650 12
- $a transplantace orgánů $x škodlivé účinky $7 D016377
- 650 12
- $a polyomavirové infekce $7 D027601
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 12
- $a nádory kůže $x patologie $7 D012878
- 650 _2
- $a TOR serin-threoninkinasy $7 D058570
- 650 12
- $a infekce onkogenními viry $x komplikace $7 D014412
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 700 1_
- $a Gómez-Tomás, A $u Department of Dermatology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain $1 https://orcid.org/0000000293885623
- 700 1_
- $a Llombart, B $u Servicio de Dermatología, Instituto Valenciano de Oncología, Valencia, Spain
- 700 1_
- $a Mendoza, D $u Department of Dermatology, Fundación Jiménez Díaz, Madrid, Spain $1 https://orcid.org/0000000260722115
- 700 1_
- $a Marcoval, J $u Department of Dermatology, Hospital de Bellvitge, IDIBELL, University of Barcelona, Barcelona, Spain $1 https://orcid.org/0000000264891872
- 700 1_
- $a Piaserico, S $u Dermatology Unit, Department of Medicine, Università di Padova, Padova, Italy $1 https://orcid.org/0000000210914733
- 700 1_
- $a Baykal, C $u Department of Dermatology, Istanbul University, Istanbul Medical Faculty, Istanbul, Turkey $1 https://orcid.org/0000000160043166
- 700 1_
- $a Bouwes-Bavinck, J N $u Department of Dermatology, Leiden University Medical Center, Leiden, The Netherlands
- 700 1_
- $a Rácz, E $u Department of Dermatology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands $1 https://orcid.org/0000000151196451
- 700 1_
- $a Kanitakis, J $u Department of Dermatology, Edouard Herriot Hospital Group, Hospices Civils de Lyon, Lyon, France $1 https://orcid.org/000000030469257X
- 700 1_
- $a Harwood, C A $u Centre for Cell Biology and Cutaneous Research, Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK $1 https://orcid.org/0000000213750965
- 700 1_
- $a Cetkovská, P $u Department of Dermatovenereology, Faculty of Medicine, Charles University, Pilsen, The Czech Republic $1 https://orcid.org/0000000288076768
- 700 1_
- $a Geusau, A $u Department of Dermatology, Medical University of Vienna, Vienna, Austria $1 https://orcid.org/000000030347065X
- 700 1_
- $a Del Marmol, V $u Service de Dermatologie, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium
- 700 1_
- $a Masferrer, E $u Department of Dermatology, Hospital Universitari Mútua de Terrassa, Barcelona, Spain $1 https://orcid.org/0000000207632815
- 700 1_
- $a Orte Cano, C $u Service de Dermatologie, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium $1 https://orcid.org/0000000215707856
- 700 1_
- $a Ricar, J $u Department of Dermatovenereology, Faculty of Medicine, Charles University, Pilsen, The Czech Republic $1 https://orcid.org/000000032079236X
- 700 1_
- $a de Oliveira, W R $u Department of Dermatology, University of São Paulo, São Paul, Brazil
- 700 1_
- $a Salido-Vallejo, R $u Department of Dermatology, University Clinic of Navarra, School of Medicine, University of Navarra, Pamplona, Spain $1 https://orcid.org/0000000172108959
- 700 1_
- $a Ducroux, E $u Department of Dermatology, Edouard Herriot Hospital Group, Hospices Civils de Lyon, Lyon, France
- 700 1_
- $a Gkini, M A $u Centre for Cell Biology and Cutaneous Research, Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK
- 700 1_
- $a López-Guerrero, J A $u Laboratory of Molecular Biology, Fundación Instituto Valenciano de Oncología, Valencia, Spain $u IVO-CIPF Joint Research Unit of Cancer, Príncipe Felipe Research Center (CIPF), Valencia, Spain $u Department of Pathology, School of Medicine, Catholic University of Valencia 'San Vicente Martir', Valencia, Spain
- 700 1_
- $a Kutzner, H $u Dermatopathologie, Friedrichshafen, Germany
- 700 1_
- $a Kempf, W $u Kempf und Pfaltz Histologische Diagnostik and Department of Dermatology, University Hospital Zurich, Zürich, Switzerland
- 700 1_
- $a Seçkin, D $u Department of Dermatology, Başkent University Faculty of Medicine, Ankara, Turkey $1 https://orcid.org/0000000178494520
- 773 0_
- $w MED00002983 $t Journal of the European Academy of Dermatology and Venereology : JEADV $x 1468-3083 $g Roč. 36, č. 11 (2022), s. 1991-2001
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/35607918 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230120 $b ABA008
- 991 __
- $a 20230131150914 $b ABA008
- 999 __
- $a ok $b bmc $g 1891592 $s 1184259
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2022 $b 36 $c 11 $d 1991-2001 $e 20220614 $i 1468-3083 $m Journal of the European Academy of Dermatology and Venereology $n J Eur Acad Dermatol Venerol $x MED00002983
- LZP __
- $a Pubmed-20230120
